Somatostatin Receptor Based Imaging and Radionuclide Therapy

Table 1

Tumor responses in patients with various NETs, treated with different radiolabeled SST analogs.

Ligand	Patient number	Tumor response				References
		CR	PR	SD	PD
octreotide	26	0	2 (8%)	21 (81%)	3 (11%)	[71]
octreotide	18	0	2 (11%)	16 (89%)	0	[72]
^90Y-DOTATOC	116	5 (4%)	26 (22%)	72 (62%)	13 (11%)	[79]
^90Y-DOTATOC	41	1 (2%)	9 (22%)	25 (61%)	6 (15%)	[80]
^177Lu-DOTATATE	310	5 (2%)	86 (28%)	158 (51%)	61 (20%)	[81]
^177Lu-DOTATATE	26	3 (12%)	7 (27%)	12 (46%)	4 (15%)	[82]
^90Y-DOTATATE and ^177Lu-DOTATATE	26	2 (7.7%)	9 (34.6%)	11 (42.3%)	4 (15.4%)	[83]
^213Bi-DOTATOC	7	1 (14%)	2 (28%)	3 (44%)	n.a.	[36]

CR: complete remission; PR: partial remission; SD: stable disease; PD: progressive disease; n.a. not available.